WONTECH
LAVIEEN
The 1927nm Thulium Laser for Brightening, Rejuvenation and Pigment Correction
Lavieen is Wontech’s advanced 1927nm Thulium fractional laser, engineered to deliver powerful skin rejuvenation and pigment correction with minimal downtime. Known globally as the “BB Laser”, Lavieen bridges the gap between ablative and non‑ablative laser resurfacing, providing visible brightening and refined skin texture with minimal patient discomfort.
Using a wavelength that targets the epidermal basal layer, where melanocytes and melanin are highly concentrated, Lavieen delivers precise sub‑ablative energy to treat pigmentation, pores, and fine lines, while preserving the stratum corneum for a faster, more comfortable recovery.
Why Clinics Choose Lavieen
Treatment Experience and Results
Lavieen treatments are typically well tolerated, with patients experiencing mild warmth or tingling. Because the stratum corneum is preserved, downtime remains minimal, often allowing makeup application within 24 hours.
A single Lavieen session can yield results comparable to multiple toning sessions, thanks to its ability to deliver energy deeper and more evenly.
Patients can expect improvements in:
- Overall radiance
- Pigment clarity
- Pore size
- Skin tone and texture
- Wrinkles and fine lines
Ideal Candidates
Lavieen is suitable for patients seeking:
- Brightening and clarity.
- Treatment for stubborn pigmentation.
- Smoother texture and pore refinement.
- Mild to moderate resurfacing with minimal downtime.
Its safety profile and epidermis‑preserving action make it especially suitable for individuals who cannot tolerate ablative CO₂ or require minimal interruption to daily life.
Why Add Lavieen to Your Clinic
Lavieen combines clinical versatility, exceptional pigment clearance, skin rejuvenation and rapid recovery making it a highly marketable device for modern aesthetics clinics. It provides effective results across multiple skin indications, while offering a gentle, comfortable patient experience aligned with today’s demand for low‑downtime treatments.